IPROOV
iProov , world leader in secure biometric authentication technology, today announced record-breaking growth in the first half of 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210728006091/en/
From January to June 2021, iProov saw a 15x increase in the number of people verified using its technology versus the same time period last year. Its flagship Genuine Presence Assurance technology solidified its global market leadership, with verifications growing at a consistent rate of 25% per month worldwide.
This has been driven by demand from organizations needing to verify the identity of online users to prevent fraud. iProov’s patented technology assures the genuine presence of an online user to ensure they are the right person, a real person, and authenticating right now.
iProov has been profitable in 2021, while at the same time growing its worldwide team by 25% to 85 staff. In April, the company welcomed cybersecurity veteran Paul King who joined iProov’s advisory board following 27 years at Cisco, most recently as Chief Security Officer. iProov has also been awarded numerous prestigious awards, including Best Biometric Solution at the 2021 Cyber Security Global Excellence Awards.
In what has been a tumultuous year across the globe, iProov’s technology has provided safe and secure digital identity verification for a growing range of vital services. Since the start of 2021, iProov has added major customers and partners to its portfolio spanning government, health, travel, financial services and ID providers.
In February iProov announced it had been selected by the Australian government to provide the liveness solution for myGovID. Millions of Australians will be able to strengthen their digital identity using a simple face scan on their mobiles, providing access to a range of government services, including online tax.
iProov’s existing service to NHS Digital in the UK became even more crucial this year. Since 2020, iProov has enabled users in England to create an NHS login remotely and securely. A user scans their identity document, such as a valid passport or driver’s license, and then completes a brief iProov face verification to confirm their identity, giving them secure access to the services of the NHS App. Since May 2021, this has included the COVID vaccination status service.
In January 2021, iProov announced a collaboration with its partner, Mvine, to trial private COVID status certificates. The solution enables an individual to register a test result or vaccination status and then securely share that status without disclosing their identity, using either paper or a smartphone. The trials, which took place in care and education settings, were backed by investment from Innovate UK and showcased how biometric verification could greatly simplify the checking of COVID status credentials while enhancing user privacy.
The iProov partner program grew by a third in the first six months of the year, from sectors including identity, health, travel and cryptocurrency. In April, Jumio, the leading provider of AI-powered end-to-end identity verification and eKYC solutions, announced that it had selected iProov technology to deliver high conversion rates, fast onboarding, a natural user experience and small SDK size to its customers.
Andrew Bud, iProov Founder and CEO, commented: “In the first half of 2021, iProov has secured users’ identities online and protected major organizations from fraud on a vast scale across the globe. The dramatic acceleration in the digital identity market, caused by the pandemic, has demonstrated our market leadership based on our unrivaled usability, inclusiveness and resilient security, and the extraordinary scalability of our platform. I am continually impressed by the remarkable work of the iProov team in successfully rising to the many challenges created by such transformative growth.”
The highlights from 2021 so far include: -
Awards
● iProov Takes Home Gold in Three Cybersecurity Excellence Awards: Government, Financial Services, and Identity Proofing & Corroboration - https://www.iproov.com/blog/cyber-security-awards-government-finance
● iProov wins Best Biometric Solution at 2021 Cyber Security Global Excellence Awards - https://www.iproov.com/blog/best-biometric-solution-cyber-security-2021
● iProov Named Winner of Coveted Global InfoSec Award During RSA Conference - https://www.iproov.com/press/iproov-winner-of-global-infosec-award-during-rsa-conference-2021
Customers and partners
● Australian Taxation Office extends national digital identity program with face verification technology from iProov - https://www.iproov.com/press/australian-taxation-office-national-digital-identity-program-face-verification-technology
● Jumio adds iProov’s award winning liveness detection to its KYC platform - https://www.iproov.com/press/jumio-adds-iproov-award-winning-liveness-detection-to-its-kyx-platform
● iProov selected by itsme to support global expansion - https://www.iproov.com/press/iproov-face-verification-selected-by-itsme-to-support-global-expansion
● COVID-19 certificate solution from iProov and Mvine moves into trial phase - https://www.iproov.com/press/uk-covid19-passport-moves-into-trial-phase
Senior team hires
● Cybersecurity veteran Paul King joins iProov’s Advisory Board - https://www.iproov.com/press/cyber-security-veteran-joins-iproov-advisory-board
-ENDS-
About iProov
Founded in 2012, iProov is the world leader in online facial biometric authentication, working with governments, financial institutions and other enterprises to securely verify customer identity. Used for effortless onboarding and authentication, customers include the U.S. Department of Homeland Security, the UK Home Office, the UK National Health Service (NHS), the Australian Taxation Office, GovTech Singapore, Rabobank, ING and others. iProov’s technologies include Liveness Assurance and Genuine Presence Assurance, which ensures that an online customer is the right person, a real person, and is authenticating right now. This protects against spoof attacks from photos, videos, masks and digital injection attacks that use deepfakes and other synthetic media. Supported by capital from private equity firm JRJ Group, iProov has grown a global footprint with offices in the UK, US and Singapore. iProov was recognized as a Gartner Cool Vendor 2020 in Identity Access Management & Fraud Detection and as the 5th fastest growing technology company in the UK in the Deloitte 2020 UK Technology Fast 50. For more information, please see www.iproov.com or follow us on LinkedIn or Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210728006091/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe's GetVocal raises $26m to scale trustworthy conversational agents for enterprises18.11.2025 10:00:00 CET | Press release
Series A led by Creandum, with Elaia and Speedinvest, will accelerate the product development of GetVocal’s AI customer experience platform GetVocal, Europe’s leading provider of conversational AI agents for enterprise customer support, today announced the closing of a $26 million Series A investment round led by Creandum with participation from Elaia and Speedinvest, bringing GetVocal’s total fundraising to $30 million. GetVocal will use the funding to fuel product innovation, market expansion, and hiring across Europe as the company accelerates its mission to help enterprises build hybrid human-AI workforces. Founded in 2023 by AI entrepreneurs Roy Moussa and Antonin Bertin, GetVocal is headquartered in Paris, with a 60-strong team spread across Europe. It serves 23 markets, with a stronghold in France and Portugal, and a rapidly growing presence in the UK and DACH. The company tackles one of the biggest barriers to conversational AI adoption – the lack of trust and confidence in bla
Ant Group Unveils China’s First Multimodal AI Assistant with Code-Driven Outputs18.11.2025 09:05:00 CET | Press release
Ant Group today launched LingGuang, a next-generation multimodal AI assistant and the first of its kind in China that interacts with users through code-driven outputs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117438567/en/ Equipped with the capability to understand and produce language, image, voice and data, LingGuang delivers precise, structured responses to complex queries through 3D models, audio clips, charts, animations, interactive maps, and even immediately generated applications, in addition to traditional text-based conversation. Designed around three key features, LingGuang aims to make complex knowledge simpler and more intuitive, transforming how users access information and interact with AI tools. Fast Research: LingGuang responds to user questions or keywords with dynamic, multimodal content, making research on any topic clearer and more engaging. Its 3D digital modeling capability transcends traditio
SkySparc Appoints Oliver Bussmann as Chairman of the Board18.11.2025 09:00:00 CET | Press release
Appointment of industry veteran follows majority growth investment from Bregal Milestone SkySparc, a trusted global provider of digital transformation solutions for treasury and finance organizations, today announced the appointment of Oliver Bussmann as Chairman of the Board, following the closing of a majority growth investment from Bregal Milestone, a leading European software private equity firm. As former Global CIO at UBS and SAP, Bussmann has a proven track record of scaling B2B software and services across the Office of the CFO, Financial Services, RegTech, and WealthTech. Throughout his career, he has guided organizations through complex SaaS transitions, strategic M&A, and go-to-market acceleration – delivering multiple successful exits and sustained enterprise growth. Bussmann will help steer SkySparc’s technology and value-creation agenda, as Chairman, leveraging his network across financial services and technology to accelerate innovation, expand AI adoption, and drive lon
European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 08:23:00 CET | Press release
Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2The new liquid formulation of infliximab, available in 100 mg and a newly introduced 350 mg presentation, eliminates the need for reconstitution and cuts drug preparation time by 51%, lowering preparation costs by 20%1,3Projected annual cost savings across seven European countries could reach up to €2.6 million, alongside significant improvements to workflow efficiency3 Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline inf
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release
After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
